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Summary
Objective: To determine the nature of alternatively spliced isoforms of fibronectin expressed in healthy bovine articular cartilage and cartilage
derived from human osteoporotic and osteoarthritic joints.
Design: Our study focused on a single alternatively spliced region of the fibronectin gene, the variable region. Bovine cartilage samples were
obtained within 12 h of slaughter and human cartilage samples were obtained within 8 h of the time of joint replacement surgery. RNA was
extracted and alternatively spliced isoforms of fibronectin were amplified using RT-PCR.
Results: Two novel alternatively spliced forms of fibronectin designated (V+I-10)− and (V+III-15)− were identified in bovine articular
cartilage. Fibronectin is composed of multiple repeats of three types of homologous units and these two novel isoforms specifically splice out
single individual repeating units. Expression of all these isoforms was dependent upon the presence of an extracellular matrix. In the human
samples the expression profiles obtained with osteoporotic hip and osteoarthritic knee cartilage was not uniform. The (V+C)− isoform was
present in all samples and the (V+I-10)− isoform was distributed between both osteoporotic and osteoarthritic cartilage. However, the
(V+III-15)− isoform was shown to be associated with osteoarthritic cartilage with statistical significance (P<0.015 ). In addition a third novel
splice variant was identified and designated as III-15X. Translation of the III-15X isoform results in a truncated form of fibronectin lacking a
significant portion of the C-terminus. Further RT-PCR analysis of several other tissue types suggests that these variants are cartilage
specific.
Conclusion: Our results demonstrate the existence of three new cartilage specific isoforms of fibronectin and indicate that expression of one
or more may be associated with osteoarthritis. © 2002 OsteoArthritis Research Society International. Published by Elsevier Science Ltd.
All rights reserved.
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Fibronectin (FN) is a 220 kDa extracellular matrix (ECM)
glycoprotein encoded by a single gene and produced by
many cell types. It is postulated to play an important role in
numerous cellular activities including adhesion, prolifer-
ation, differentiation, cytoskeletal organization, wound heal-
ing and apoptosis1,2. FN exists as a hetero- or homo-dimer
cross-linked by disulfide bonds. Each FN monomer is
composed of multiple repeats of three types of homologous
units, designated I, II and III. A number of mRNA alternative
splicing events occur at three sites, extra type III domain A
(ED-A), extra type III domain B (ED-B) and the variable
region (V) also known as the type III-connecting segment
(III-CS). The ED-A and ED-B domains are encoded
by single exons while the V domain in humans has
been shown to contain two 5′-splice donor sites and
three 3′-splice acceptor sites producing five potential
isoforms3–6.528The ECM of articular cartilage comprises predominantly
type II collagen and the aggregating proteoglycan, aggre-
can. It also contains a number of minor components, such
as FN, which have both structural and signalling roles7.
Several recent studies in the dog, horse and rabbit have
examined the FN isoforms expressed in cartilage and
demonstrated an unusual population distribution, including
an isoform found exclusively in cartilage8. This isoform,
designated (V+C)− accounts for 50–80% of FN transcripts
in cartilage and lacks the V domain as well as the fifteenth
type-III repeat (III-15) and the tenth type-I repeat (I-10)7–9.
Recent studies have demonstrated that the (V+C)− isoform
forms dimers only with other (V+C)− monomers10. The
precise role of the (V+C)− isoform in the ECM of cartilage
has not been elucidated. However, cartilage homeostasis is
regulated in part by the interaction of chondrocytes with
extracellular matrix components and FN is known to play a
role in chondrocyte adhesion and mechano-transduction
signalling events11, suggesting that alternatively spliced
forms of fibronectin might have a regulatory role in these
processes.
In this study we have examined FN splicing in bovine
articular cartilage and have identified two novel alterna-
tively spliced forms whose expression is dependent upon
the presence of an extracellular matrix. We have extended
this analysis to cartilage derived from human osteoarthritic
and osteoporotic joints and show that these two novel
splice forms are expressed in humans and appear to be
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EXPERIMENTAL SAMPLES
Bovine articular cartilage was obtained from the
metacarpal-phalangeal joints of cows (aged 18–24 months)
within 12 h of slaughter. Human hip femoral head cartilage
(osteoporosis patients aged 56–71 years) and tibial plateau
knee cartilage [osteoarthritis (OA) patients aged 54–76
years] was obtained within 8 h of the time of joint replace-
ment. Tissue was collected under the approval of the
local ethical committee.CHONDROCYTE CULTURE
Chondrocytes were isolated by collagenase digestion as
follows: 0.5 g of diced cartilage (3×3×1 mm) was incu-
bated in 5 ml Dulbecco’s Modified Eagles Medium (DMEM,
Life Technologies) containing 10 mg/ml bacterial colla-
genase (Sigma), 25 mM HEPES, pH 7.5 for 2 h at 37°C
with constant mixing before being filtered through a 70 m
cell strainer. Chondrocytes were then recovered from the
media by centrifugation and washed once in PBS before
plating at a density of 1.5×103 cells per cm2. Cartilage
explants were maintained in DMEM with 100 U/ml penicillin
(Sigma) and 100 g/ml streptomycin (Sigma) with media
changes every 2 days. Isolated chondrocytes and the
human cell lines, HepG2 (hepatoma ATCC No. HB-8065)
and SW1353 (chondrosarcoma ATCC No. HTB-94) were
maintained as monolayers in DMEM with 10% (v/v)
FCS (Gibco BRL), 100 U/ml penicillin and 100 g/ml
streptomycin and passaged after reaching confluence.RNA ISOLATION
Isolation of total RNA was carried out using RNAzol B
reagent (Biogenesis Inc, U.S.A.). Bovine and human articu-
lar cartilage were diced (3×3×1 mm) and 0.5 g wet-weight
immediately placed in 0.5 ml of RNAzol B. Monolayercultures were extracted by direct application of RNAzol B
(2 ml per 75 cm2). Samples were then processed as
described by the manufacturer. The quality of the RNA
isolated from the OA derived chondrocytes was variable as
assessed by agarose gel electrophoresis. The osteoporo-
sis derived chondrocytes consistently yielded high quality
RNA. The disparity is likely to be a consequence of the
diseased state of the osteoarthritic cartilage.Fig. 1. (A) A schematic diagram of the FN protein domain structure highlighting the alternatively spliced ED-A, ED-B and variable regions.
(B) a schematic highlighting the position of the PCR primer pairs used to examine alternative splicing in the variable region.RT-PCR, CLONING AND SEQUENCE ANALYSIS
For RT-PCR, first strand cDNA was synthesized from
total RNA using Superscript II reverse transcriptase (Life
Technologies). 1 g of RNA was reverse transcribed in a
final volume of 20 l using random hexamer oligonucle-
otides as primers. Human multiple tissue cDNAs were
obtained commercially (Clontech, U.S.A.). Oligonucleotide
primer positions in the V region are indicated in Fig. 1. The
nucleotide sequences were as follows: VDF: 5′-TATG
AAGTGAGTGTCTATGCTCT-3′; VDR: 5′-TTCTGCCACTG
TTCTCC-3′8; FNIII-14F: 5′-GGGTCTCCTCCCAGAGA
AGT-3′; FNI-10R: 5′-CGAGTCATCCGTAGGTTGGT-3′;
FNIII-15F: 5′-TCCTGTTGGCACTGATGAAG-3′; FNI-11R:
5′-GCTCATCATCTGGCCATTTT-3′ and type II collagen
T2F: 5′-GGAGATCCGGGCTGAGGGCAACA-3′ and T2R:
5′-GAATGGGCGTCAGGTCAGGTCAGC-3′. GAPDH
primers were obtained from Stratagene. All transcripts were
amplified from 1 l of first strand cDNA reaction using
Expand DNA polymerase (Boehringer). PCR reactions con-
tained 25 pmol of each primer, 0.2 mM dNTPs and 0.5 U
Expand DNA polymerase in a final volume of 25 l, and
were amplified for 35 cycles of 94°C for 30 s, 60°C for 30 s
and 72°C for 60 s, followed by a final extension period
of 72°C for 10 min. Reaction products were resolved in
agarose gels alongside 1 kb DNA ladder (GibcoBRL),
stained with ethidium bromide (10 g/ml) and visualized by
UV transillumination. For cloning, amplified cDNA frag-
ments were gel purified, using the QIAquick procedure
(QIAGEN) and ligated into pCR2.1-TOPO (Invitrogen) fol-
lowing the manufacturer’s instructions. Recombinant plas-
mids were transformed into TOP10 E. coli (Invitrogen),
grown in L-Broth containing ampicillin (100 g/ml) and
purified by anion-exchange chromatography following the
manufacturer’s instructions (QIAGEN). DNA sequence wascartilage-specific. In addition a third splice variant
which encodes a truncated form of FN was identified in
osteoarthritic cartilage. This data raises the possibility that
these isoforms have specific roles in maintaining structural
integrity or regulating ‘outside-in’ signaling in chondrocytes.
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(Prizm ABI 377).STATISTICAL ANALYSIS
The significance of the distibution of FN splice variants
was determined using a two-tailed Fisher’s exact test.ResultsSPLICING PATTERN OF FN IN BOVINE ARTICULAR CARTILAGE
To investigate alternative splice forms of FN (shown
schematically in Fig. 1), RT-PCR was performed using
VDF/VDR primer pairs with cDNA prepared from bovine
metacarpal–phalangeal articular cartilage and the human
cell lines, SW1353 (chondrosarcoma) and HepG2
(hepatoma). Based upon previously described splicing
events this analysis was predicted to produce up to four V+
products, a V− product and additionally, in cartilage, the
cartilage-specific (V+C)− product8. Figure 2 shows that
these products were successfully amplified with the
expected distribution. In addition, in the cartilage sample
there were two additional products intermediate in size
between the V− and (V+C)− transcripts. These were
cloned, sequenced and found to correspond to alternatively
spliced transcripts which, if translated, would specifically
delete the amino acid sequences of the variable region
and either the fifteenth type III domain (III-15) or the tenthtype I domain (I-10). We have designated these isoforms
(V+III-15)− and (V+I-10)− respectively. The nucleotide
sequences have been submitted to the EMBL/Genbank
databases under accession numbers AJ320525 &
AJ320526.SPLICING PATTERN OF FN IN HUMAN ARTICULAR CARTILAGE
To determine whether the novel splice forms were also
present in human tissue, RNA was derived from human hip
femoral head cartilage obtained at the time of joint replace-
ment surgery. RT-PCR analysis indicated splicing in the V
domain [Fig. 3(A)]. The splice forms identified included the
(V+I-10)− and (V+III-15)− isoforms as well as the pre-
viously described V+, V-, and (V+C)− isoforms. The (V+I-
10)− and (V+III-15)− PCR products were cloned and
sequenced to confirm their identity. The nucleotide
sequences have been submitted to the EMBL/Genbank
databases under accession numbers AJ320528 &
AJ320529.
The splicing profile of the V-region of FN in other human
tissues was determined using RT-PCR [Fig. 3(B)]. The
(V+III-15)−, (V+I-10)− and (V+C)− splice variants were not
detected in heart, placenta, liver or lung.Fig. 2. RT-PCR analysis of bovine articular cartilage FN splice
variants in the C-terminal region spanning the III-12 to the I-12
domains. RNA was isolated from bovine metacarpal–phalangeal
articular cartilage and two human cell lines, SW1353 and HepG2,
cultured in monolayer. RT-PCR was carried out using the VDF and
VDR primers as described in Materials and Methods and separ-
ated by agarose gel electrophoresis. (A) Lane 1—bovine articular
cartilage, Lane 2—SW1353, Lane 3—HepG2, Lane 4—water
control. SM—size markers. (B) The cartilage specific RT-PCR
products obtained from the bovine articular cartilage sample were
recovered and DNA sequenced. The schematic illustrates the FN
splice variants identified. Those domains subject to alternative
splicing are shown hatched.Fig. 3. The (V+III-15)− and (V+I-10)− FN isoforms are present in
human articular cartilage and are cartilage specific. (A) RNA was
extracted from human articular cartilage derived from hip femoral
head. RT-PCR was carried out using the VDR and VDF primers as
described in Materials and Methods. Lane 1—human femoral head
cartilage, Lane 2—water control. SM—size markers. (B) RT-PCR
reactions were carried out using the VDF and VDR primers with
cDNA derived from heart, lung, liver, placenta (Clontech) and hip
femoral head cartilage.SPLICING PATTERN IN HUMAN OSTEOPOROTIC AND
OSTEOARTHRITIC CARTILAGE
To determine whether FN isoform expression was
altered in disease we compared the expression profiles
using RNA derived from seven human osteoporotic hip
femoral head cartilage samples and ten human osteoar-
thritic knee tibial plateau cartilage samples. In order to
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pairs were designed to focus on individual splice variants.
For all primer pairs the agarose gel results for three of the
osteoporotic and four of the osteoarthritic samples are
shown in Figs 4 and 5 and the complete data set is detailed
in Table I.
The primer pair III-14F/I-10R enabled us to assess
specific expression of the (V+III-15)− isoform as it could
not amplify the (V+I-10)− isoform. The (V+III-15)− isoform
was detected in one of the seven osteoporotic femoral
head cartilage samples (sample 1, Table I) and eight of the
10 osteoarthritic tibial plateau cartilage samples (Fig. 4 &
Table I). Using a two-tailed Fishers exact test expression of
the (V+III-15)− isoform in osteoarthritic cartilage was
shown to be statistically significant (P=0.015). The longer
V+ isoforms were successfully amplified in the osteoporotic
samples but were not detected in the osteoarthritic
samples. This is probably a consequence of the quality of
the RNA obtained from the tissue reducing the synthesis of
longer cDNA products.
The primer pair III-15F/I-11R enabled us to look at
specific expression of the (V+I-10)− isoform. As shown in
Fig. 5 and Table I this isoform was detected in all seven of
the osteoporotic cartilage samples but was found only in
three of the osteoarthritic samples. Using a two-tailed
Fisher’s exact test expression of the (V+I-10)−isoform in
osteoporotic cartilage was shown to be statistically signifi-
cant (P=0.01). An additional PCR product was detected in
four of the osteoarthritic samples (Fig. 5). This product was
cloned, sequenced and shown to correspond to a FN
isoform resulting from a splice event which removed 139
nucleotides from within the III-15 domain. Translation of this
DNA sequence demonstrates that the result of the splicing
event is the introduction of a frame shift resulting in theaddition of four new amino acids in the III-15 domain before
premature termination of the coding sequence. It is poss-
ible that additional 5′ splicing events associated with this
isoform might correct for this frame shift but this would
probably result in significant alteration of the upstream
amino acid sequence. We have designated this splice
variant III-15X and deposited it in the EMBL/Genbank
databases under accession number AJ320527.EXPRESSION OF NOVEL FN ISOFORMS IS MATRIX DEPENDENT
To examine whether these additional splice variants
were expressed in a matrix dependent manner, as has
been described for the (V+C)− isoform9, a single bovine
metacarpal–phalangeal joint was used to establish carti-
lage explant cultures, and to isolate and seed chondrocytes
in monolayer culture. RNA was isolated from these culture
systems as well as directly from the original tissue. RT-PCR
analysis was carried out as described in Materials and
methods. Figure 6 indicates that the splicing profile after 14
days of explant culture was identical to that of cartilage
extracted directly after removal from the joint. However, the
chondrocyte monolayer culture showed a time dependent
loss of the (V+C)− transcript and the novel (V+III-15)− and
(V+I-10)− isoforms. This loss was associated with the
decreased expression of type II collagen.Fig. 4. Expression of the (V+III-15)− isoform in human osteoarthritic and osteoporotic cartilage. (A) RNA was extracted from human articular
cartilage derived from osteoporotic hip femoral head and osteoarthritic knee tibial plateau. RT-PCR was carried out using the FNIII-14F and
FNI-10R primers as described in Materials and methods. The results for three osteoporotic (OP) samples and four osteoarthritic samples are
shown, as well as a water control and size markers (SM). (B) A schematic diagram of the isoforms indicating the position of the primers and
the expected PCR product sizes.
A
BEXAMINATION OF GENOMIC DNA SEQUENCE OF THE HUMAN
FN GENE
Examination of the described FN exon–intron organiza-
tion shows that the novel (V+III-15)−, (V+I-10)−and III-15X
isoforms are all generated by splicing events between
532 A. E. Parker et al.: Cartilage-specific variants of fibronectinFig. 5. Expression of the (V+I-10)− isoform in human osteoarthritic and osteoporotic cartilage. (A) RT-PCR was carried out using the
FNIII-15F and FNI-11R primers as described in Materials and methods. The results for the three osteoporotic (OP) samples and four
osteoarthritic samples used in Fig. 4 are shown, as well as a water control and size markers (SM). The position of the novel III-15X isoform
is indicated. (B) A schematic diagram of the isoforms indicating the position of the primers and the expected PCR product sizes.
A
BTable I
Distribution of FN splice variants
Pathology (V+C)− (V+I-10)− (V+III-15)− III-15X
OP Y Y Y N
OP Y Y N N
OP Y Y N N
OP Y Y N N
OP Y Y N N
OP Y Y N N
OP Y Y N N
OA Y Y Y N
OA Y Y N N
OA Y Y N N
OA Y N Y Y
OA Y N Y Y
OA Y N Y Y
OA Y N Y Y
OA Y N Y N
OA Y N Y N
OA Y N Y N
Two-tailed
Fisher’s exact test NA P=0.01** P=0.015* P=0.103
The presence or absence of each FN splice variant was deter-
mined by RT-PCR. The statistical significance of the distribution
was determined using a two-tailed Fisher’s exact test .Fig. 6. Expression of novel FN isoforms is dependent upon the
presence of the extracellular matrix. Cartilage and chondrocytes
were cultured as described, RNA extracted and RT-PCR carried
out using primers specific for FN, Type II collagen and GAPDH.
Lane 1—bovine articular cartilage from the metacarpal–phalangeal
joint extracted on day 1, Lane 2—bovine articular cartilage
extracted after explant culture for 14 days, Lane 3—primary bovine
chondrocytes were isolated from the metacarpal–phalangeal joint
and extracted after 7 days in monolayer culture, Lane 4–primary
bovine chondrocytes isolated from the metacarpal-phalangeal joint
and extracted after 14 days in monolayer culture, Lane 5—water
control. Size markers (SM).known exons. The formation of a complete III-15 domain
requires appropriate splicing of two exons. In the case of
the III-15X isoform the second exon is skipped leading to
the potential frame-shift and premature termination codon.
Sequence analysis of the two III-15X exons identifiespurine rich elements (PREs) immediately upstream of both
of the 5′ donor sites. PREs have recently been shown to
exert a regulatory effect upon splicing of the ED-B exon in
FN12.
Osteoarthritis and Cartilage Vol. 10, No. 7 533Fig. 7. Human FN genomic organization. The human FN cDNA is depicted spanning from the end of the III-14 domain to the end of the I-11
domain. The position of the introns is marked in the sequence and indicated on the right are the identity of the spliced domains. The positions
of several putative purine rich elements (PREs) upstream of 5′ acceptor sites are underlined.Discussion
We have examined the mRNA splicing events in the
variable region of the FN gene and have identified two
novel cartilage specific isoforms of FN designated (V+III-
15)− and (V+I-10)−. Both variants are expressed in juvenile
bovine articular cartilage and adult human articular carti-
lage. This is the first description of multiple splicing events
in humans involving the sequences encoding the III-15 and
I-10 domains.
It has been reported previously that the major FN isoform
in equine and canine cartilage is (V+C)−8. Our RT-PCR
experiments confirm that this observation extends to
human cartilage. The relative intensities of PCR products
suggest that the novel (V+III-15)− and (V+I-10)−isoforms
may be minor species, although it should be noted that
RT-PCR is not a truly quantitative measure. We have
examined the expression profiles of the FN splice forms in
osteoporotic hip and osteoarthritic knee cartilage and
established that in the 17 samples analysed expression of
the (V+III-15)− isoform was significantly associated with
osteoarthritic cartilage (P=0.015) while expression of the
(V+I-10)− isoform was associated with osteoporotic carti-
lage (P=0.01). Due to the nature of the clinical material
obtained, the possibility remains that this distribution is
related to location, hip vs knee, rather than disease. A third
isoform designated III-15X was also identified only in the
osteoarthritic samples. This isoform is the result of a splice
event within the III-15 domain and in the absence of more
5′ splicing events results in a frame shift leading to the
addition of four novel amino acids in the III-15 domain
before premature termination of the coding sequence. Both
the (V+III-15)− and the (V+I-10)− isoforms are expressed
in bovine juvenile cartilage, whereas in adult human carti-
lage expression appears to be differential. There may be
distinct roles for each isoform in early developing cartilage
vs mature adult tissue.
We have also confirmed that expression of the (V+C)-
isoform is dependent upon the presence of an ECM and
that this is also the case for the (V+III-15)− and (V+I-10)-
isoforms9. When chondrocytes were isolated and cultured
in the absence of a matrix, expression of the (V+III-15)−,
(V+I-10)− and (V+C)− isoforms was lost within 7 days and
this was coincident with the loss of expression of type II
collagen. Thus, expression of these isoforms of FN
appears to be associated with a chondrocytic phenotypeand lost during the dedifferentiation observed when
chondrocytes are placed in monolayer culture.
Alternative splicing of the V region was observed
between all four described donor and acceptor splice sites
when only the V region was subject to splicing. However,
only the most 5′ and most 3′ sites were used in splicing
events involving the III-15 and I-10 sequences. A recent
study has shown that the splicing of the ED-B exon is
regulated in part by purine-rich elements (PREs) which act
as enhancer elements and are required for accurate 5′
splice site selection in the absence of a strong consensus
sequence12. A separate study has also implicated TGCATG
repeats in regulating ED-B splicing13. The critical sequence
elements required to regulate 3′ splice site selection have
not yet been identified; however, splicing suppressors have
been described in the FN ED-A exon which rely on second-
ary structure for activity14,15. In the cartilage specific splic-
ing profiles we have described PREs are located
immediately upstream of the majority of the splice sites.
These sequences may be involved in regulating the
choice of 5′ splice site selection through interaction with
chondrocyte-specific splicing factors.
We have demonstrated the existence of mRNA species
for the (V+III-15)− and (V+I-10)− variants. If these isoforms
of FN are expressed then one can speculate on their
functional significance. The III-15 and I-10 segments have
been implicated in regulating the rate of matrix assembly,
and loss of either of these domains would significantly
impair the ability of fibronectin to incorporate into the
cartilage ECM environment16. The III-15 domain may also
be required for binding to chondroitin sulfate, the major
glycosaminoglycan attached to aggrecan17,18. Conse-
quently selective deletion of the III-15 or I-10 domains may
impact upon rate and type of matrix synthesized. Studies
using deminectins, truncated FN constructs, have indicated
that the (V+C)− isoform is secreted as a homodimer and is
not capable of heterodimerization with V+ isoforms10. Also,
a mutant FN lacking the I-10 to I-12 region when expressed
in COS cells is secreted with monomers exceeding dimers
by two to one. It remains to be determined whether the
(V+III-15)−and (V+I-10)− isoforms are expressed as pro-
teins and would be able to heterodimerize with the (V+C)−
isoform or favor monomeric secretion.
In addition FN is involved in ‘outside-in’ signaling events
via interactions with several integrins and a number of other
534 A. E. Parker et al.: Cartilage-specific variants of fibronectinECM molecules, for instance the RGD site in the tenth type
III repeat has been shown to interact with the 51 and the
v1 integrins, while the V and III-14 domains are recog-
nized by the 41 integrin19. All of these integrins are
expressed by chondrocytes20. There are also many
domains in FN which contain cryptic activities only realized
by conformational change or proteolytic cleavage. Expres-
sion of the III-15X variant lacking sequences C-terminal to
the III-15 domain would prevent dimerization and possibly
expose a sequence within the III-14 domain that has been
shown to have antiadhesive properties21,22. Deletion of the
V region in concert with either the III-15 or I-10 domains is
likely to cause conformational changes in the surrounding
domains and may impact upon the associated matrix
interactions or signalling events. It may also alter the
relative susceptibility to proteolytic cleavage. In OA
elevated levels of FN and catabolic FN fragments are found
in the cartilage and synovial fluid. Loss of the V, III-15
and/or I-10 domains may alter the type of fragments
generated.
In conclusion, this study describes three additional splic-
ing events that occur in the sequence encoding the V, III-15
and I-10 regions of FN. The (V+III-15)− and (V+I-10)−
isoforms appear to be cartilage-specific and their expres-
sion is dependent upon an extracellular matrix. The
RT-PCR analysis, while not being truly quantitative, implies
that the (V+III-15)−, (V+I-10)− and III-15X isoforms are
minor splice variants in cartilage when compared with the
predominant (V+C)− isoform. The physiological role of
these variants in normal and diseased cartilage remains to
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